Arvinas Inc (ARVN)

Currency in USD
6.19
-0.05(-0.79%)
Real-time Data·
ARVN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ARVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.096.27
52 wk Range
5.9029.61
Key Statistics
Prev. Close
6.24
Open
6.24
Day's Range
6.09-6.27
52 wk Range
5.9-29.61
Volume
1.23M
Average Volume (3m)
2.08M
1-Year Change
-74.39%
Book Value / Share
8.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.78
Upside
+203.36%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings upwards for the upcoming period

Arvinas Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Arvinas Inc Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company’s products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Inc SWOT Analysis


Clinical Setbacks
Explore Arvinas's strategic shift following discontinued trials and workforce reduction, impacting its clinical development pipeline and financial outlook
Vepdegestrant Potential
Delve into the promising prospects of Arvinas's lead candidate for ESR1 mutant breast cancer patients, with NDA filing expected in 2H 2025
Market Dynamics
Uncover the challenges Arvinas faces in the competitive oral SERD market, balancing innovation against established benchmarks and emerging rivals
Financial Outlook
Analyst targets range from $10 to $48, reflecting varied perspectives on Arvinas's future amid extended cash runway and strategic realignment
Read full SWOT analysis

Arvinas Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS beat at -$0.84 vs -$0.94 forecast, but revenue missed at $22.4M vs $34.42M expected
  • Stock dropped 10.96% post-earnings to $6.78; further 3.42% decline in pre-market trading
  • Cost-cutting measures extended cash runway into 2028; R&D expenses reduced from $93.7M to $68.6M
  • Advancing clinical programs including NDA submission for Vepdeg; seeking new partner for collaboration
  • CEO transition ongoing; company focusing on neuroscience and oncology pipeline development
Last Updated: 06/08/2025, 14:50
Read Full Transcript

Compare ARVN to Peers and Sector

Metrics to compare
ARVN
Peers
Sector
Relationship
P/E Ratio
−6.2x−2.6x−0.5x
PEG Ratio
−0.080.050.00
Price/Book
0.7x1.6x2.6x
Price / LTM Sales
1.2x1.4x3.3x
Upside (Analyst Target)
132.4%170.2%43.4%
Fair Value Upside
Unlock16.0%7.1%Unlock

Analyst Ratings

12 Buy
9 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 18.78
(+203.36% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.84 / -0.94
Revenue / Forecast
22.40M / 34.42M
EPS Revisions
Last 90 days

ARVN Income Statement

People Also Watch

18.51
SRPT
+3.06%
138.47
KRYS
+1.74%
25.63
CNC
+1.45%
179.81
ALAB
+5.22%
2.569
CLLS
-3.41%

FAQ

What Stock Exchange Does Arvinas Trade On?

Arvinas is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Arvinas?

The stock symbol for Arvinas is "ARVN."

What Is the Arvinas Market Cap?

As of today, Arvinas market cap is 455.92M.

What Is Arvinas's Earnings Per Share (TTM)?

The Arvinas EPS (TTM) is -1.00.

When Is the Next Arvinas Earnings Date?

Arvinas will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is ARVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Arvinas Stock Split?

Arvinas has split 0 times.

How Many Employees Does Arvinas Have?

Arvinas has 430 employees.

What is the current trading status of Arvinas (ARVN)?

As of 08 Aug 2025, Arvinas (ARVN) is trading at a price of 6.19, with a previous close of 6.24. The stock has fluctuated within a day range of 6.09 to 6.27, while its 52-week range spans from 5.90 to 29.61.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.